ArticleExploratory research in clinical and social pharmacy2026
Medication adherence in epilepsy: Validation of the short medication adherence scale (SMAS-7) and mediation analysis of quality-of-life pathways.
Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication adherence is a key modifiable determinant of outcomes in epilepsy and may represent an important pathway linking psychosocial and treatment-related burdens to quality of life (QOL). However, its role within these pathways remains insufficiently understood, partly due to the lack of brief, multidimensional, validated measures in this population. Objectives: This study aimed to validate the Short Medication Adherence Scale (SMAS-7) in adults with epilepsy and to examine whether medication adherence mediates the associations of financial wellbeing, mental health, cognitive difficulties, and antiepileptic drug (AED) adverse effects with QOL. Methods: A cross-sectional study was conducted among 649 adults with epilepsy recruited from community pharmacies and a primary healthcare center. Confirmatory factor analysis, measurement invariance, reliability, construct validity, and receiver operating characteristic (ROC) analyses were used to validate the SMAS-7. Mediation analyses were performed using structural equation modeling with 5000 bootstrap resamples, adjusting for age, gender, access to healthcare, seizure characteristics, and seizure control. A Monte Carlo simulation confirmed adequate statistical power to detect indirect effects. Results: The SMAS-7 demonstrated excellent structural validity, confirming a three-factor model with excellent fit (χ Conclusion: The SMAS-7 is a valid, reliable, and clinically useful tool for assessing medication adherence in adults with epilepsy. When each predictor was considered individually, medication adherence showed partial indirect associations linking financial wellbeing, mental health burden, and AED adverse effects with QOL; however, these associations were attenuated to near zero in a mutually adjusted model including all four predictors simultaneously, indicating that they reflect pathway-specific associations rather than an independent mediating effect of adherence. Medication adherence nonetheless remains a clinically relevant, modifiable target within a multidimensional approach to patient-centered epilepsy care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.